MEDICAMEQ — Medicamen Biotech Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Annual income statement for Medicamen Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,154	1,409	1,793	1,625	1,978
Cost of Revenue
Gross Profit	499	549	698	605	960
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	976	1,232	1,640	1,558	1,854
Operating Profit	179	176	153	67.9	124
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	181	170	131	98.8	120
Provision for Income Taxes
Net Income After Taxes	149	147	94.9	65.6	98
Minority Interest
Net Income Before Extraordinary Items
Net Income	149	148	109	71.1	96.4
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	149	148	109	71.1	96.5
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	12.2	11.9	8.68	5.59	7.22
Dividends per Share